Clinical Trial

Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 28, 2024 (before its estimated January 4, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in primary DIPG patients (NCI-CTCAE V5.0).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-01-29.
Trial Details
NCT Number NCT05717712
Lead Sponsor Capital Medical University
Conditions Oncolytic Virus, Diffuse Intrinsic Pontine Glioma, Adverse Drug Event
Enrollment 18 participants
Start Date 2023-01-04
Primary Completion 2025-01-04 (estimated)
Study Completion 2028-01-04 (estimated)
Updated on ClinicalTrials.gov 2024-02-28